NCT06719232 Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation
| NCT ID | NCT06719232 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jahn Ferenc South Pest Teaching Hospital |
| Condition | Interstitial Cystitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-10-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate a catheter-free method for delivering medications directly into the bladder, known as intravesical instillation, which is commonly used to treat conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS), recurrent urinary tract infections, bladder cancer, and post-chemotherapy or post-radiation cystitis. The study investigates whether this method, which eliminates the need for catheterization, reduces discomfort and complications while maintaining treatment effectiveness. By collecting data on patient experiences and outcomes, the study seeks to determine if this approach provides a safer and more comfortable alternative to traditional catheter-based treatments.
Eligibility Criteria
Inclusion Criteria: * Male and female patients aged between 18 and 80 years. * Patients for whom the treating physician has determined that intravesical instillation is necessary due to one of the following conditions: * Interstitial cystitis/bladder pain syndrome (IC/BPS). * Recurrent urinary tract infections (UTIs). * Non-muscle invasive bladder cancer. * Post-radiation cystitis. * Post-chemotherapy cystitis. * Negative urine culture within the last two weeks. * Patients who provide verbal and written informed consent to participate in the study. Exclusion Criteria: * Urinary tract infection within the past month or currently active infection. * Diagnosed bleeding disorders or recurrent macroscopic hematuria. * Post-void residual urine volume greater than 100 ml. * Mental condition that prevents reliable cooperation.
Contact & Investigator
Peter Tenke, Professor of Urology
STUDY CHAIR
South Pest Teaching Hospital
Frequently Asked Questions
Who can join the NCT06719232 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Interstitial Cystitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06719232 currently recruiting?
Yes, NCT06719232 is actively recruiting participants. Contact the research team at bkoves@gmail.com for enrollment information.
Where is the NCT06719232 trial being conducted?
This trial is being conducted at Budapest, Hungary, Budapest, Hungary.
Who is sponsoring the NCT06719232 clinical trial?
NCT06719232 is sponsored by Jahn Ferenc South Pest Teaching Hospital. The principal investigator is Peter Tenke, Professor of Urology at South Pest Teaching Hospital. The trial plans to enroll 300 participants.